Loading...
•
Mar 31, 2024
InspireMD Q1 2024 Earnings Report
InspireMD reported first quarter 2024 financial results with revenue increase and progress in clinical trials.
Key Takeaways
InspireMD reported a 22.0% increase in revenue to $1.51 million for Q1 2024, driven by growth in existing markets. The company sold over 2,500 stents during the quarter, marking a total of over 50,000 stents sold to date. The company is focused on advancing the C-GUARDIANS PMA clinical trial and anticipates potential FDA approval in the first half of 2025.
Total revenue increased by 22.0% to $1.51 million compared to Q1 2023.
Over 2,500 stents were sold during the quarter, up 25.6% year-over-year.
Gross profit decreased by 21.6% to $292,000 due to higher training costs.
Net loss totaled $7.03 million, or $0.21 per share, compared to a net loss of $4.26 million, or $0.53 per share, for the same period in 2023.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company anticipates and prepares for a launch of its best-in-class carotid platforms in the U.S. in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...